Keywords: Nafithromycin
This is an open access article distributed under the terms of the Creative Commons Share Alike 4.0 International License which allows others to remix, tweak, and build upon the work non commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Copyright © 2026: Ansari Vikhar Danish Ahmad et al.
Attribution Non CommercialVol. 13 (1): 01-02, Jan-June, 2026.
DOI: http://doi.org/10.56511/JIPBS.2026.13101
India's groundbreaking antibiotic, Nafithromycin, marks a significant milestone in the fight against antimicrobial resistance. Developed indigenously, it offers a potent solution to drug-resistant infections. This innovative therapy not only showcases India's pharmaceutical advancements but also provides a critical tool in addressing global health challenges posed by resistant pathogens.
In a major breakthrough for the pharmaceutical industry, India launched its first indigenously developed antibiotic, Nafithromycin (marketed as Miqnaf®). Developed by Wockhardt, in collaboration with the Biotechnology Industry Research Assistance Council (BIRAC), Nafithromycin represents a critical step in the global fight against antimicrobial resistance (AMR). The antibiotic is specifically designed to address the growing threat of community-acquired bacterial pneumonia (CABP), a lifethreatening infection exacerbated by drug-resistant bacteria [1].
AMR has emerged as one of the most pressing health threats globally, causing an estimated 39 million deaths by 2050, with drug-resistant pneumonia accounting for millions of deaths annually. India, which bears a significant portion of the global burden of pneumonia, suffers from alarming resistance rates to critical antibiotics, including a marked decline in the efficacy of drugs such as imipenem. This has - which claims over two million lives each year worldwide [2- 4].
Nafithromycin offers a potential solution. The drug is ten times more potent than azithromycin, a commonly used antibiotic, and presents a three-day regimen for treating CABP, enhancing patient adherence and reducing the duration of therapy. The macrolide mechanism of action of this novel antibiotic, which inhibits bacterial protein synthesis by binding to the 23S rRNA in the 50S ribosome subunit, effectively targets both gram-positive and certain gram-negative bacteria, making it an essential tool for combating respiratory, skin, and sexually transmitted infections [1, 2].
Dr. Jitendra Singh, Union Minister for Science and Technology, hailed Nafithromycin’s launch as a game changer in the global fight against AMR. With India contributing 23% of the global pneumonia burden, this drug is expected to play a pivotal role in reducing mortality rates associated with CABP, which can reach as high as 47% in severe cases [1].
Nafithromycin’s development journey spans 14 years and involves an investment of ₹500 crores, with clinical trials conducted in the U.S., Europe, and India. The final approval of the drug by the Central Drugs Standard Control Organization (CDSCO) on January 2, 2025, marked a milestone in the treatment of CABP in adults. The launch of Nafithromycin not only addresses the urgent need for leadership in pharmaceutical innovation and public-private collaboration in healthcare [1].
With global antibiotic consumption expected to increase by 16.3% between 2016 and 2023, the introduction of Nafithromycin is a timely reminder of the need for continued research and investment in novel antimicrobial agents. This innovation sets a promising precedent for the development of future treatments for multidrug-resistant infections, offering hope for millions of patients worldwide [2-4].
AMR: Antimicrobial Resistance; CABP: Communityacquired bacterial pneumonia; E. coli: Escherichia coli; rRNA: Ribosomal ribonucleic acid.
The authors would like to thank principal, Y. B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus, Aurangabad 431001, Maharashtra, India for providing the necessary facilities and research support.
The authors declare no competing interests.
Not applicable.
All authors are contributed equally in this work.
None
This manuscript has utilized OpenAI's ChatGPT (version 4) to enhance the clarity and coherence of the language. The tool was employed exclusively for language improvement purposes with ethical and academic standards. The authors take full responsibility for the content and integrity of the manuscript.